[go: up one dir, main page]

CL2016002441A1 - Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación. - Google Patents

Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación.

Info

Publication number
CL2016002441A1
CL2016002441A1 CL2016002441A CL2016002441A CL2016002441A1 CL 2016002441 A1 CL2016002441 A1 CL 2016002441A1 CL 2016002441 A CL2016002441 A CL 2016002441A CL 2016002441 A CL2016002441 A CL 2016002441A CL 2016002441 A1 CL2016002441 A1 CL 2016002441A1
Authority
CL
Chile
Prior art keywords
preparation
same
taxane
tablet
solid amorphous
Prior art date
Application number
CL2016002441A
Other languages
English (en)
Inventor
Yong Ii Kim
Jae Hyun Park
Jong Soo Woo
Ho Taek Im
Shanmugam Srinivasan
Young Su Yoon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54240734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002441(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CL2016002441A1 publication Critical patent/CL2016002441A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>DISPERSIÓN SÓLIDA AMORFA QUE COMPRENDE UN TAXANO; MÉTODO DE PREPARACIÓN DE LA MISMA Y COMPRIMIDO QUE LA COMPRENDE.</p>
CL2016002441A 2014-03-31 2016-09-28 Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación. CL2016002441A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2014/002734 WO2015152433A1 (en) 2014-03-31 2014-03-31 Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same

Publications (1)

Publication Number Publication Date
CL2016002441A1 true CL2016002441A1 (es) 2017-02-17

Family

ID=54240734

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002441A CL2016002441A1 (es) 2014-03-31 2016-09-28 Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación.

Country Status (33)

Country Link
US (1) US9867801B2 (es)
EP (1) EP3125872B1 (es)
JP (1) JP6539675B2 (es)
KR (1) KR101851571B1 (es)
CN (1) CN106255496B (es)
AR (1) AR099886A1 (es)
AU (1) AU2015242738B2 (es)
BR (1) BR112016022528B1 (es)
CA (1) CA2944438C (es)
CL (1) CL2016002441A1 (es)
CU (1) CU24486B1 (es)
DK (1) DK3125872T3 (es)
DO (1) DOP2016000262A (es)
ES (1) ES2748686T3 (es)
GT (1) GT201600208A (es)
HU (1) HUE046616T2 (es)
IL (1) IL247977B (es)
LT (1) LT3125872T (es)
MA (1) MA39361B1 (es)
MX (1) MX373189B (es)
MY (1) MY175387A (es)
PE (1) PE20161477A1 (es)
PH (1) PH12016501825B1 (es)
PL (1) PL3125872T3 (es)
PT (1) PT3125872T (es)
RU (1) RU2684632C2 (es)
SA (1) SA516371952B1 (es)
SG (1) SG11201607456RA (es)
SI (1) SI3125872T1 (es)
TW (1) TWI706793B (es)
UA (1) UA117610C2 (es)
UY (1) UY36055A (es)
WO (2) WO2015152433A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3380079A4 (en) * 2015-11-25 2019-08-21 Patheon Development Services Inc. AMORPHOUS DISPERSION GRANULES AND PHARMACEUTICAL FORMS FOR ORAL USE
MA44987A (fr) * 2016-05-09 2019-03-20 Dispersol Technologies Llc Formulations de médicaments améliorées
CN110742895A (zh) * 2017-03-30 2020-02-04 复旦大学附属中山医院 Fxr激动剂在制备治疗脂肪肉瘤药物中的用途
TWI833710B (zh) * 2017-10-06 2024-03-01 香港商慧源香港創新有限公司 高單位含量口服型紫杉烷組合物及方法
WO2019094688A1 (en) * 2017-11-10 2019-05-16 Dispersol Technologies, Llc Improved drug formulations
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
CN109851593B (zh) * 2019-02-01 2021-04-16 沈阳药科大学 基于淋巴介导转运的甘油三酯前药及其制备方法
CN110105368B (zh) * 2019-05-09 2022-01-07 上海大学 去氧紫杉烷类似物及其制备方法
IL320609A (en) * 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
JP7731883B2 (ja) * 2019-12-02 2025-09-01 アストラゼネカ・アクチエボラーグ ６－（２－クロロ－６－メチルピリジン－４－イル）－５－（４－フルオロフェニル）－１，２，４－トリアジン－３－アミンの固形製剤処方物
WO2021177930A1 (en) * 2020-03-06 2021-09-10 Vyshnevskyy Ihor Anatoliyovych Pharmaceutical composition with increased solubility of gesperidine and method of its preparation
EP4225747A1 (en) 2020-10-07 2023-08-16 Athenex, Inc. Acetamido-phenyltetrazole derivatives and methods of using the same
WO2022271765A1 (en) * 2021-06-23 2022-12-29 Blueprint Medicines Corporation Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
EP4479092A1 (en) * 2022-02-14 2024-12-25 Purdue Research Foundation Polymer salts for improved drug delivery from amorphous solid dispersions
KR20240151747A (ko) * 2022-03-08 2024-10-18 (주)씨앤팜 도세탁셀 또는 이의 약학적으로 허용 가능한 염을 포함하는 약학적 조성물 및 이의 제조방법
CN115429766B (zh) * 2022-09-08 2023-10-27 江苏集萃新型药物制剂技术研究所有限公司 淫羊藿苷固体分散体、复方药物双层片剂及其制备方法与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230338B1 (hu) 1997-06-27 2016-02-29 Abraxis Bioscience Llc Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
KR20030041577A (ko) * 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
CA2540104A1 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles comprising inclusion complexes
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
CN1840196A (zh) * 2006-01-27 2006-10-04 无锡杰西医药科技有限公司 一种适用于难溶性药物的分散剂
WO2007073389A1 (en) * 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
EP2190413B1 (en) * 2007-08-24 2015-01-28 Stichting Het Nederlands Kanker Instituut Compositions for the treatment of neoplastic diseases
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
GB0716591D0 (en) 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
MX2010008138A (es) * 2008-01-25 2010-08-10 Gruenenthal Gmbh Forma de dosis farmaceutica.
CN101632630A (zh) * 2008-07-24 2010-01-27 北京诺美医药科技有限公司 一种普罗布考固体分散体
JP2012500788A (ja) * 2008-08-22 2012-01-12 スティヒティング ヘット ネーデルランド カンケル インスティテュート 組成物
JP5751868B2 (ja) * 2010-03-30 2015-07-22 日東電工株式会社 フィルム状製剤及びその製造方法
KR20130109092A (ko) * 2010-06-09 2013-10-07 아보트 러보러터리즈 키나제 억제제를 함유하는 고체 분산물
ES2524408T5 (es) * 2010-11-19 2022-04-25 Gilead Sciences Inc Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato
US20150011525A1 (en) * 2011-09-13 2015-01-08 Isp Investments Inc. Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer
CN102357075A (zh) * 2011-09-30 2012-02-22 武汉平华生物医药科技有限公司 一种多西他赛纳米制剂及其制备方法

Also Published As

Publication number Publication date
KR20160124904A (ko) 2016-10-28
AR099886A1 (es) 2016-08-24
TWI706793B (zh) 2020-10-11
EP3125872A1 (en) 2017-02-08
SA516371952B1 (ar) 2020-12-07
SG11201607456RA (en) 2016-10-28
UY36055A (es) 2016-09-30
MA39361A1 (fr) 2017-06-30
DK3125872T3 (da) 2019-10-14
KR101851571B1 (ko) 2018-04-26
AU2015242738B2 (en) 2019-09-26
RU2016136636A3 (es) 2018-09-25
MA39361B1 (fr) 2018-06-29
BR112016022528A2 (pt) 2017-08-15
IL247977A0 (en) 2016-11-30
SI3125872T1 (sl) 2019-11-29
EP3125872A4 (en) 2017-10-11
US20170112799A1 (en) 2017-04-27
IL247977B (en) 2019-09-26
WO2015152433A1 (en) 2015-10-08
BR112016022528B1 (pt) 2023-04-11
AU2015242738A1 (en) 2016-09-22
PE20161477A1 (es) 2017-01-29
RU2016136636A (ru) 2018-05-03
UA117610C2 (uk) 2018-08-27
ES2748686T3 (es) 2020-03-17
DOP2016000262A (es) 2017-01-15
JP2017509653A (ja) 2017-04-06
HUE046616T2 (hu) 2020-03-30
GT201600208A (es) 2018-11-27
LT3125872T (lt) 2019-10-10
PH12016501825A1 (en) 2016-11-07
CU24486B1 (es) 2020-11-30
MX2016012596A (es) 2017-01-09
PT3125872T (pt) 2019-10-24
EP3125872B1 (en) 2019-08-14
PH12016501825B1 (en) 2021-06-23
MY175387A (en) 2020-06-23
CA2944438C (en) 2021-10-26
JP6539675B2 (ja) 2019-07-03
TW201620506A (zh) 2016-06-16
CN106255496A (zh) 2016-12-21
US9867801B2 (en) 2018-01-16
RU2684632C2 (ru) 2019-04-11
NZ723991A (en) 2021-01-29
CA2944438A1 (en) 2015-10-08
PL3125872T3 (pl) 2020-03-31
MX373189B (es) 2020-04-21
WO2015152544A1 (en) 2015-10-08
CN106255496B (zh) 2019-10-18

Similar Documents

Publication Publication Date Title
CL2016002441A1 (es) Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación.
EP3201762A4 (en) Dynamic code deployment and versioning
EP3132650A4 (en) Systems and methods for concurrent spectrum usage within actively used spectrum
EP3193608A4 (en) Carm1 inhibitors and uses thereof
EP3145689A4 (en) Layerless bioprinting via dynamic optical projection and uses thereof
EP3211018A4 (en) Composition for heat-dissipation members, heat-dissipation member, electronic device, and heat-dissipation-member production method
EP3178265A4 (en) Systems and methods for dual-connectivity operation
EP3141051A4 (en) Systems and methods for dual-connectivity operation
EP3141589A4 (en) Composition for heat-dissipation members, heat-dissipation member, and electronic device
EP3100557A4 (en) Systems and methods for dual-connectivity operation
EP3100578A4 (en) Systems and methods for dual-connectivity operation
EP3223291A4 (en) Input operation device
EP3122408A4 (en) Pressurizing masks, systems and methods
PL3137585T3 (pl) Urządzenie do przekształcania odpadów stałych na olej syntetyczny, gaz i nawóz
EP3163081A4 (en) Gas compression device
EP3100829A4 (en) Hydraulic hammering device
EP3100828A4 (en) Hydraulic hammering device
EP3130130A4 (en) Dynamic contextual device networks
EP3198468A4 (en) Dynamic data management
EP3180715A4 (en) Dynamic feature set management
AU2015245230B2 (en) Polymeric rule die, and formulations therefor
EP3109229A4 (en) Water-soluble propofol derivatives and uses thereof
EP3169827B8 (de) Stahlkolbenring, und verfahren zur herstellung desselben
EP3267280A4 (en) Reaction force output device
EP3232755A4 (en) Component housing member, and component housing method